Rotavirus infection remains a major cause of mortality in children less than 5 years old, we now have live attenuated orally administered rotavirus vaccines in more than 112 countries. There is some evidence that in areas of high mortality, some vaccines may not be so effective and of course, there may be difficulties in accessing the vaccines in some low to middle income countries. In The Lancet Infectious Diseases, a paper from Bangladesh and one from India, present further evidence to help improve the likelihood of a successful programme, given these challenges. Kanungo S et al Lancet Infectious Diseases 2022;22:1191-1199 https:// doi.org/10.1016/S1473-3099(22)00161-X have examined the safety and efficacy of two commonly available rotavirus vaccine preparations administering them in an interchangeable dosing schedule in an open label open-label, randomised, controlled, non-inferiority trial.
展开▼
